Share on StockTwits
 

NPS Pharmaceuticals (NASDAQ:NPSP) issued its quarterly earnings data on Thursday. The company reported $0.07 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.02 by $0.05, ARN reports. The company had revenue of $54.45 million for the quarter, compared to the consensus estimate of $44.22 million.

Shares of NPS Pharmaceuticals (NASDAQ:NPSP) opened at 37.62 on Thursday. NPS Pharmaceuticals has a one year low of $7.65 and a one year high of $39.68. The stock has a 50-day moving average of $36.26 and a 200-day moving average of $29.74. The company’s market cap is $3.869 billion.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of NPS Pharmaceuticals in a research note on Wednesday, February 19th. They now have a $40.00 price target on the stock. On the ratings front, analysts at Needham & Company raised their price target on shares of NPS Pharmaceuticals from $28.00 to $46.00 in a research note on Wednesday, February 19th. They now have a “buy” rating on the stock. Finally, analysts at Jefferies Group downgraded shares of NPS Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, February 19th. They now have a $38.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. NPS Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $40.29.

In other NPS Pharmaceuticals news, Director Georges Gemayel unloaded 6,188 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $37.70, for a total value of $233,287.60. Following the transaction, the director now directly owns 9,000 shares in the company, valued at approximately $339,300. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.